Table 2.
Univariable and multivariable logistic regression analysis of predictive factors for pCR in HER2-positive and triple negative (TN) subtypes.
| Parameters | HER2-Positive/TN | Univariable Analysis | Multivariable Analysis | |||||
|---|---|---|---|---|---|---|---|---|
| pCR (N = 22) |
Residual Tumor (N = 60) |
OR | 95% CI | p Value | OR | 95% CI | p Value | |
| T stage | ||||||||
| 1–2 | 20 (38%) | 33 (62%) | 8.18 | 1.75–38.16 | 0.007 | |||
| 3–4 | 2 (7%) | 27 (93%) | 1.00 | |||||
| Clinical anatomic stage | ||||||||
| IIA-IIIA | 20 (30%) | 46 (70%) | 3.04 | 0.63–14.66 | 0.165 | |||
| IIIB-IIIC | 2 (12%) | 14 (88%) | 1.00 | |||||
| Histologic grade | ||||||||
| 1-2 | 8 (21%) | 30 (79%) | 1.00 | |||||
| 3 | 11 (28%) | 28 (72%) | 1.47 | 0.52–4.19 | 0.468 | |||
| Missing | 3 | 2 | ||||||
| Ki-67 | ||||||||
| Low, <30% | 8 (24%) | 25 (76%) | 1.00 | |||||
| High, ≥30% | 9 (20%) | 35 (80%) | 0.80 | 0.27–2.37 | 0.692 | |||
| Missing | 5 | 0 | ||||||
| ER status | ||||||||
| Positive | 4 (15%) | 23 (85%) | 1.00 | 1.00 | ||||
| Negative | 18 (33%) | 37 (67%) | 2.80 | 0.84–9.31 | 0.093 | 8.37 | 1.75–40.1 | 0.008 |
| Metabolic parameters a | ||||||||
| MTVcsc (cm3) | 0.9 (0.3–1.7) |
2.8 (0.1–38.0) |
0.37 | 0.19–0.72 | 0.003 | 0.12 | 0.02–0.74 | 0.022 |
| TLGcsc | 5.0 (1.4–38.5) |
19.5 (0.2–593.4) |
0.92 | 0.86–0.98 | 0.010 | |||
| CSC proportion (%) | 15.9 (6.1–31.8) |
21.5 (5.6–39.1) |
0.94 | 0.87–1.00 | 0.068 | |||
| SUVmax | 6.3 (3.3–28.7) |
8.2 (3.4–23.7) |
0.93 | 0.82–1.06 | 0.271 | |||
| MTV (cm3) | 4.6 (1.7–13.8) |
13.3 (1.2–170.7) |
0.85 | 0.76–0.95 | 0.005 | |||
| TLG | 17.1 (4.7–111.3) |
57.6 (3.3–1386.9) |
0.98 | 0.96–0.99 | 0.011 | |||
| MTV40% (cm3) | 3.6 (1.7–13.8) |
9.1 (1.2–90.3) |
0.78 | 0.65–0.93 | 0.005 | |||
| TLG40% | 16.0 (4.7–66.3) |
47.0 (3.3–1006.1) |
0.96 | 0.94–0.99 | 0.008 | |||
a Continuous variables, values are median (range). Bold values are statistically significant. TN: triple negative; OR: odds ratio; CI: confidence interval; MTVcsc: metabolic tumor volume for cancer stem cell; TLGcsc: total lesion glycolysis for cancer stem cell.